A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the efficacy of oral 882C87 compared with oral acyclovir in the treatment of
localized herpes zoster in immunocompromised patients. To assess the safety and tolerance of
oral 882C87 in immunocompromised patients.